Home/Pipeline/ANK-800

ANK-800

Multiple Sclerosis

Phase 1Active

Key Facts

Indication

Multiple Sclerosis

Phase

Phase 1

Status

Active

Company

Anokion

About Anokion

Anokion is a clinical-stage biotech pioneering a platform for antigen-specific tolerance induction to treat autoimmune diseases. Its core technology leverages the liver's natural immune tolerance pathways to re-educate the immune system to ignore specific self-antigens, offering a potentially curative and safer alternative to broad immunosuppressants. The company is advancing a pipeline of programs for celiac disease and multiple sclerosis, backed by experienced leadership and venture capital investors. As a private entity, its success hinges on clinical validation, platform expansion, and future strategic partnerships or financing.

View full company profile

Therapeutic Areas

Autoimmune Diseases Celiac Disease Multiple Sclerosis

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active